Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab monotherapy in advanced recurrent ovarian cancer
NL-OMON47631Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Objective response rate in Cohort A all-comers, Objective response rate in Cohort A PD-L1-high subgroup and 2 more. Started May 2016; status: active, not recruiting.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON47631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47631.